Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 22 01 2020
revised: 18 05 2020
accepted: 06 07 2020
pubmed: 12 7 2020
medline: 12 1 2021
entrez: 12 7 2020
Statut: ppublish

Résumé

Under conditions of inherent or induced mitochondrial dysfunction, cancer cells manifest overlapping metabolic phenotypes, suggesting that they may be targeted via a common approach. Here, we use multiple oxidative phosphorylation (OXPHOS)-competent and incompetent cancer cell pairs to demonstrate that treatment with α-ketoglutarate (aKG) esters elicits rapid death of OXPHOS-deficient cancer cells by elevating intracellular aKG concentrations, thereby sequestering nitrogen from aspartate through glutamic-oxaloacetic transaminase 1 (GOT1). Exhaustion of aspartate in these cells resulted in immediate depletion of adenylates, which plays a central role in mediating mTOR inactivation and inhibition of glycolysis. aKG esters also conferred cytotoxicity in a variety of cancer types if their cell respiration was obstructed by hypoxia or by chemical inhibition of the electron transport chain (ETC), both of which are known to increase aspartate and GOT1 dependencies. Furthermore, preclinical mouse studies suggested that cell-permeable aKG displays a good biosafety profile, eliminates aspartate only in OXPHOS-incompetent tumors, and prevents their growth and metastasis. This study reveals a novel cytotoxic mechanism for the metabolite aKG and identifies cell-permeable aKG, either by itself or in combination with ETC inhibitors, as a potential anticancer approach. SIGNIFICANCE: These findings demonstrate that OXPHOS deficiency caused by either hypoxia or mutations, which can significantly increase cancer virulence, renders tumors sensitive to aKG esters by targeting their dependence upon GOT1 for aspartate synthesis. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/17/3492/F1.large.jpg.

Identifiants

pubmed: 32651261
pii: 0008-5472.CAN-20-0246
doi: 10.1158/0008-5472.CAN-20-0246
pmc: PMC7484159
mid: NIHMS1611580
doi:

Substances chimiques

Ketoglutaric Acids 0
Nitrogen N762921K75

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3492-3506

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK123095
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215431
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA160458
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA251543
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215410
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA201483
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Cell Metab. 2015 Aug 4;22(2):304-11
pubmed: 26212717
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Nat Cell Biol. 2019 Jan;21(1):63-71
pubmed: 30602761
Mol Cell. 2014 Mar 6;53(5):710-25
pubmed: 24560926
Nat Cell Biol. 2018 Jul;20(7):775-781
pubmed: 29941933
Cell. 2016 Jul 28;166(3):555-566
pubmed: 27471965
Cancer Cell. 2011 Oct 18;20(4):524-37
pubmed: 22014577
PLoS One. 2014 Nov 24;9(11):e113865
pubmed: 25420025
Nature. 2016 Aug 31;537(7621):544-547
pubmed: 27580029
Cancer Cell. 2014 Dec 8;26(6):840-850
pubmed: 25490448
Cell Rep. 2017 Jun 27;19(13):2665-2680
pubmed: 28658616
Mol Cell Biol. 2002 Oct;22(20):7004-14
pubmed: 12242281
Cancer Genet. 2012 Jul-Aug;205(7-8):377-90
pubmed: 22867999
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3434-E3443
pubmed: 28396387
Oncogene. 2006 Aug 7;25(34):4663-74
pubmed: 16892080
Nature. 2014 Jun 19;510(7505):397-401
pubmed: 24828042
Cell Metab. 2016 Apr 12;23(4):580-9
pubmed: 27076075
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14087-91
pubmed: 22891333
Autophagy. 2014 May;10(5):930-2
pubmed: 24675140
Cell Metab. 2016 Nov 8;24(5):716-727
pubmed: 27746050
Science. 2008 May 2;320(5876):661-4
pubmed: 18388260
Nature. 2011 Nov 20;481(7381):380-4
pubmed: 22101433
Mol Cell Biol. 2007 May;27(9):3282-9
pubmed: 17325041
Nat Chem Biol. 2015 Jan;11(1):9-15
pubmed: 25517383
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180
pubmed: 28938091
Cell Rep. 2017 Oct 31;21(5):1331-1346
pubmed: 29091770
Cell Rep. 2016 Oct 11;17(3):876-890
pubmed: 27732861
Nat Chem Biol. 2017 May;13(5):494-500
pubmed: 28263965
Hum Mol Genet. 2015 Apr 1;24(7):1977-90
pubmed: 25504047
Cell. 2015 Jul 30;162(3):540-51
pubmed: 26232224
Cancer Cell. 2011 Sep 13;20(3):315-27
pubmed: 21907923
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24
pubmed: 15647368
Cancer Cell. 2005 Aug;8(2):143-53
pubmed: 16098467
Nature. 2011 Nov 20;481(7381):385-8
pubmed: 22101431
Mol Cell. 2013 Jul 25;51(2):236-48
pubmed: 23747014
Cancer Genet Cytogenet. 2010 Jan 1;196(1):45-55
pubmed: 19963135
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Nat Cell Biol. 2018 Jul;20(7):782-788
pubmed: 29941931
Trends Endocrinol Metab. 2012 Nov;23(11):552-9
pubmed: 22858391
Metab Eng. 2017 Sep;43(Pt B):187-197
pubmed: 27847310
Nat Genet. 2002 Apr;30(4):406-10
pubmed: 11865300
Cell Metab. 2013 Mar 5;17(3):372-85
pubmed: 23473032
Mol Cancer Res. 2016 Nov;14(11):1087-1096
pubmed: 27578770
Cell Rep. 2019 Apr 16;27(3):820-834.e9
pubmed: 30995479
J Biol Chem. 1965 Feb;240:582-7
pubmed: 14275107
Cell. 2015 Jul 30;162(3):552-63
pubmed: 26232225
Clin Cancer Res. 2013 Jul 1;19(13):3345-52
pubmed: 23633457
Cell Rep. 2017 Oct 24;21(4):1036-1047
pubmed: 29069586

Auteurs

Hanumantha Rao Madala (HR)

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.

Iiro Taneli Helenius (IT)

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.

Wen Zhou (W)

Division of Nephrology and Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Evanna Mills (E)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Cell Biology, Harvard Medical School, Boston, Massachusetts.

Yiyun Zhang (Y)

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.

Yan Liu (Y)

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.

Ana M Metelo (AM)

Center for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.

Michelle L Kelley (ML)

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.

Surendra Punganuru (S)

Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.

Kyung Bo Kim (KB)

College of Pharmacy, University of Kentucky, Lexington, Kentucky.

Benjamin Olenchock (B)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Eugene Rhee (E)

Division of Nephrology and Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Andrew M Intlekofer (AM)

Memorial Sloan Kettering Cancer Center, New York, New York.

Othon Iliopoulos (O)

Center for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.

Edward Chouchani (E)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Cell Biology, Harvard Medical School, Boston, Massachusetts.

Jing-Ruey Joanna Yeh (JJ)

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts. jyeh1@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH